OncoMatch/Clinical Trials/NCT07680764
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Is NCT07680764 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Pumitamig and Imzokitug for locally advanced non-small cell lung cancer (nsclc).
Treatment: Pumitamig · Imzokitug — The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR actionable genomic alteration
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: ALK actionable genomic alteration
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: ROS1 actionable genomic alteration
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: BRAF v600e
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: MET exon 14 skipping
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: RET fusion
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: NTRK1 fusion
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: NTRK2 fusion
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: NTRK3 fusion
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Excluded: KRAS g12c
Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immuno-oncology therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0170 · Athens, Georgia
- Local Institution - 0034 · Lexington, Kentucky
- Local Institution - 0171 · Lexington, Kentucky
- Local Institution - 0123 · Baltimore, Maryland
- Local Institution - 0180 · Hattiesburg, Mississippi
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07680764 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR actionable genomic alteration is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK actionable genomic alteration is an exclusion criterion.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages